The Topical Niacin Skin Flush Test in First Episode Psychosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

107 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to gather normative data from healthy adults and to determine a sensitive and specific cut-off value for responders and non-responders to the Niacin Skin Flush Test in a sample of first episode psychosis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Niacin Skin Flush Response in Patients With Schizophrenia

NCT02458924

Schizophrenia

COMPLETED PHASE2/PHASE3

Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

NCT00063297

Schizophrenia

COMPLETED PHASE2

Examining Persistence in Smokers With Schizophrenia

NCT03346291

Smoking Cessation Schizophrenia Schizo Affective Disorder

COMPLETED NA

Oxytocin Add on Study for Stable Schizophrenic Patients

NCT00506909

Schizophrenia

TERMINATED NA

SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia

NCT01234298

Negative Symptoms of Schizophrenia

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychotic Disorders Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control

Caucasian males and females between 19 and 30 years of age.

skin test

Intervention Type OTHER

four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.

First Episode Psychosis

Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.

skin test

Intervention Type OTHER

four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin test

four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* caucasian
* within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS
* outpatient

Exclusion Criteria

* known allergy to study compound (methyl nicotinate, vitamin B3, niacin)
* skin conditions (e.g., dermatitis, psoriasis, eczema)
* diagnosis or treatment for medical conditions that may affect normal vascular tone (e.g., diabetes, vasculitis, chronic hypertension, etc.)
* Use of anti-inflammatory, antibiotic, or antihistamine medications within one month prior to study entry
* Use of supplements like Omega 3 fatty acids within 3 months prior to study entry
* Use of vitamin or nutritional supplement containing a dose of niacin/nicotinic acid above 50 mg/day at study entry

Minimum Eligible Age

19 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes